Effects of metformin combined with drospirenone ethinylestradiol on sex hormones and blood glucose metabolism indexes in patients with polycystic ovarian syndrome
Objective To investigate the clinical effect of metformin combined with drospirenone ethinylestradiol in the treatment of polycystic ovarian syndrome(PCOS).Methods A total of 100 patients with PCOS who were treated in Zhengzhou Second People's Hospital in 2021 were selected as the research objects.According to the random number table method,the patients were divided into control group and observation group,with 50 cases in each group.The control group was treated with drospirenone ethinylestradiol,and the observation group was treated with metformin combined with drospirenone ethinylestradiol.The clinical symptoms,sex hormone indexes,glucose metabolism indexes and adverse reactions were compared between the two groups.Results After treatment,the scores of modified Ferriman-Gallwey(mF-G)and Global Acne Grading System(GAGS)in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the levels of luteinizing hormone(LH),follicle-stimulating hormone(FSH)and anti-mullerian hormone(AMH)in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the levels of fasting plasma glucose(FPG),fasting lisulin(FINS)and insulin resistance index in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Metformin combined with drospirenone ethinylestradiol is more effective in the treatment of PCOS,which can improve clinical symptoms,sex hormones and blood glucose metabolism indexes.Moreover,this combination therapy is relatively safe and worthy of further clinical promotion and application.
NETL
NSTL
万方数据
维普
